15 Development of antiviral therapeutics emphasizes minimization of the effective dose and maximization 16 of the toxic dose, first in cell culture and later in animal models. Long-term success of an antiviral 17 therapeutic is determined not only by its efficacy but also by the duration of time required for drug-18 resistance to evolve. We have developed a microfluidic device comprised of ~6000 wells, with each 19 well containing a microstructure to capture single cells. 
emergence has outpaced the discovery and development of compounds capable of treating these 36 pathogens. Because sporadic outbreaks come, go, and may never come again, development of 37 broad-spectrum therapeutics exhibiting high barriers to resistance would have the greatest value. 38
Unbiased screening of chemical libraries for antiviral agents using cell-based assays have no 39
problem identifying active compounds of high potency. However, identifying the target and 40 predicting the likelihood for evolution of resistance generally takes years of effort following 41 compound discovery. 42
As a part of a study evaluating PV infection dynamics on the single-cell level, we 43 observed that a chain-terminating antiviral ribonucleotide selectively eliminates the most-fit 44 members of the viral population (Guo et al., 2017) . This class of antiviral agent has always been 45 touted as having a high barrier to resistance (Jordheim et al., 2013) . The typical explanation for 46 this high barrier is that amino acid substitutions in the active site of the viral RNA polymerase 47 conferring resistance to the antiviral ribonucleoside also impair the specificity and/or efficiency 48 of incorporation of natural ribonucleotides (Carroll et al., 2003) . Elimination of the most-fit 49 members of the viral population by an antiviral agent requires that resistance emerge from the 50 surviving, low-fitness member of the population, which would ultimately require restoration of 51 fitness for the population to survive the myriad mechanisms of host restriction (Andino and 52 ribonucleoside, 2'-C-Me-A, is the prototype for the HCV RdRp inhibitor, sofosbuvir and related 99 compounds (Eltahla et al., 2015) . In a previous study, we evaluated infections that survived 100 treatment when present at a concentration that reduces the number of infections by 50% (IC50). 101
To our surprise, we observed selective ablation of cells infected with virus variants capable of the 102 fastest rates of replication and the highest yields of replicated RNA (Guo et al., 2017) . This 103 experiment suffered from the inability to evaluate concentrations of drug higher than the value of 104 the IC50. Here, we use 2'-C-Me-A to validate the new device. 105
For all experiments reported herein, we infect HeLa S3 cells off chip with PV engineered 106 to express enhanced green fluorescent protein (PV-eGFP) at a multiplicity of infection of 0.5 107 plaque-forming units per cell (PFU/cell), pellet and wash cells to remove free virus, suspend cells 108 to a density of 5 × 10 5 cells/mL, and load the microfluidic device. Each well is monitored for 109 eGFP fluorescence every 30 min for a 24 h period, which gives rise to a population of time 110 courses exhibiting substantial between-cell variability (Fig. S4a) . We plot the percentage of 111 infected cells as a function of drug concentration and fit to a hyperbola to obtain a value for the 112 IC50 value. In the case of 2'-C-Me-A, concentrations greater than 50 µM exhibit toxicity 113 (Stuyver et al., 2006) ; therefore, these data do not fit to a hyperbola (Fig. S4b) . It is clear from 114 this experiment, however, that the approach is sensitive enough to acquire data for a complete 115 dose-response analysis (Fig S4b) . 116 8 A major advantage of the single-cell platform is that the effect of a drug on the viable 117 population can be determined. To analyze the single-cell data, we use five phenomenological 118 parameters extracted from each time course (Fig. S4c) . These parameters are: maximum 119 fluorescence observed, which correlates to yield of genomic RNA; slope at the time of half-120 maximum fluorescence, which correlates to replication speed; infection time, which, to a first 121 approximation, is the time it takes for an infection to go from start to finish akin to the virus 122 generation time; start-point, which is the earliest time in which fluorescence can be detected; and 123 midpoint, the time of half-maximum fluorescence. This analysis leads to a distribution of values 124
formed from values measured in each cell. Our statistical analysis uses an unpaired two-tailed t-125 test to determine if a significant difference exists for the means of a given parameter under two 126 experimental conditions. In these experiments, the area under the curve defining the distribution 127 reflects the number of events monitored. We do not attempt to interpret a difference in the "fine" 128 structure of the distributions. concentrations, we observed a statistically significant difference compared to the control for all 155 parameters: maximum (Fig. 2b) ; slope (Fig. 2c) ; infection time (Fig. 2d) ; start point (Fig. 2e) ; 156 and midpoint (Fig. 2f ). This outcome with rupintrivir is clearly distinct from that above with 2'-157 C-Me-A. We conclude that not all antiviral agents interfere with the viral population in the same 158 manner or at the same stage(s) of the lifecycle. 159 were compared to that in the absence of drug using a t-test. A single asterisk indicates a p-value 164 less than 0.05; two asterisks indicate a p-value is less than 0.005. Numerical values for 165 experimental parameters are provided in Table S3 and statistical analysis in Table S4 therapeutics to cellular proteins is that the likelihood for evolution of resistance is minimized 177 (Geller et al., 2007) . 178
We have used geldanamycin (GA), because it is a potent inhibitor of HSP90 (nM range) 179 that is active against PV (Geller et al., 2007) . The presence of GA reduced the number of 180 infections established by 22 ± 4% with an IC50 value of 30 ± 8 nM (Fig. 3a) . An earlier study 181 did not observe an impact of GA prior to virus assembly; however, it is possible that a reduction 182 of the magnitude shown here would be concealed by experimental error (Geller et al., 2007) . 183
Because infection is monitored by eGFP, which requires virus entry, genome replication, and 184 genome translation, interference with any of these steps would lead to a reduction in the number 185 of eGFP-positive cells. It is clear, however, that translation and folding of eGFP are not altered in 186 the presence of the highest concentration of GA used in this experiment (Fig. S5) . 187
Analysis of the single-cell data is presented in Tables S5 and S6. The mean of the 188 distribution of values for the maximum parameter did not change in the presence of GA (Fig. 3b) , 189 in contrast to the inhibitors targeting viral proteins. Observation of a statistically significant 190 difference in the distribution of the values for the infection-time parameter was concentration 191 dependent (Fig. 3d) . A statistically significant difference for mean of the distributions for the 192 remaining parameters was observed at concentrations corresponding to the IC50 and above (Figs.  193   3c, 3e and 3f) . A third signature of antiviral action is therefore revealed with GA. 194
Given the interest in using HSP90 inhibitors as therapeutics for cancer, a variety of 195 compounds exist (Hwang et Fig. S6 to that in Fig. 3a) , has a higher affinity for HSP90 than GA ( observed when either drug is used alone. We evaluated the ability of 2'-C-Me-A to synergize 220 with GA by treating cells with the concentrations of one or both at their IC50 values (Fig. 4a) . In 221 the absence of drug, 34 ± 3% of cells in the device were infected. That number was reduced to 18 222 ± 2%, 30 ± 3%, or 15 ± 3% in the presence of 2'-C-Me-A, GA, or the combination thereof, 223
respectively. Based on this observation alone, the conclusion would be that this combination of 224 antiviral agents is not even additive. Analysis of the entire single-cell dataset is presented in 225 Tables S9 and S10. Because 2'-C-Me-A exhibits the most substantial antiviral effect relative to 226 the DMS0 control, here we compare the combination to 2'-C-Me-A alone. We observed a 227 statistically significant difference for all parameters (Figs. 4b -4f) . Single-cell analysis therefore 228 has the ability to reveal efficacy of drug combinations masked at the population level. We 229 performed the comparable experiment with GS and reached the same conclusion (Fig. S7 , Tables 230 S10 and S11). 231 presence of the combination were compared to that in the presence of GA alone using a t-test. 237
Numerical values for experimental parameters are provided in Table S9 and statistical analysis in 238 With this perspective in mind, it is not surprising that our previous evaluation of an 272 antiviral ribonucleotide using a single-cell approach revealed the unexpected finding that the 273 most-fit members of the viral population were most susceptible to this class of compounds (Guo 274 et al., 2017) . This observation left one major unresolved question: do all effective antiviral 275 therapeutics target the same subpopulation of viruses or do unique signatures exist for distinct 276 mechanistic classes of antiviral therapeutics? Addressing these questions is the central objective 277 of this study. 278
Our first-generation microfluidic device for on-chip investigation of viral infection 279 dynamics relied on cell density as the mechanism to achieve isolation of single cells in wells of 280 the device, an approach which leaves most wells of the device empty (Guo et al., 2017) . We have 281 19 redesigned the device to add physical cell-trapping structures to each well. The outcome of 282 which is the ability to achieve single-cell occupancy of ~90% of the ~6000 wells of the device 283 (Figs. 1, S1-S3) . The enhanced occupancy enabled the complete characterization of antiviral 284 therapeutics by permitting the acquisition of complete dose-response curves (e.g. Fig. 2a) . 285
The three classes of antiviral therapeutics chosen target a viral polymerase (2'-C-286 methyladenosine, 2'-C-Me-A, Fig. S4), a viral protease (rupintrivir, Fig. 2) , or a host factor, 287 HSP90, (geldanamycin, GA, Fig. 3; ganetespib, GS, Fig. S6) . Our data-analysis pipeline 288 emphasizes five phenomenological parameters with correlates to traditional parameters for 289 assessment of the viral lifecycle. 7 The major finding of this study is that each class of antiviral 290 therapeutics exhibited a unique signature with respect to the five phenomenological parameters 291 measured and so much so that it was possible to use principal component analysis (PCA) to 292 stratify the different therapeutic classes (Fig. 5) . Importantly, both GA and GS overlapped by 293 PCA despite their substantial differences in structure and efficacy (Fig. 5) . 294
To our knowledge, this study represents the first analysis of a range of antiviral 295 therapeutics on viral infection dynamics at the single-cell level. The resolution afforded by this 296 approach is unprecedented when compared to other cell-based approaches, which only provide a 297 measure of efficacy. Given the substantial effort required to go from compound to mechanism 298 using the traditional experimental paradigm, the ability of single-cell analysis to inform 299 mechanism should make this approach a welcome addition to the drug discovery and 300 development toolbox. It is not uncommon for analogues to be synthesized during the drug-301 development process that lose specificity or even function by a different mechanism of action, 302 single-cell analysis has the potential to reveal changes such as these at the start of the analysis 303 instead of much, much later in the development process. 
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